KPIs & Operating Metrics(New)

Balance Sheet

Cash Flow Statement

Acquisitions Amortization of Goodwill Amortization of Goodwill Capital Expenditures Capital Expenditures Cash from Discontinued Operations Cash from Discontinued Operations Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Divestments Dividends Paid - Common Dividends Paid - Common Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased Short-Term Debt issuances

Daily Values

Growth Metrics

Clorox (CLX) Asset Writedowns and Impairment (2021 - 2023)

Clorox has reported Asset Writedowns and Impairment over the past 2 years, most recently at $445.0 million for Q1 2023.

Quarterly results put Asset Writedowns and Impairment at $445.0 million for Q1 2023, changed N/A from a year ago — trailing twelve months through Jun 2024 was $445.0 million (changed 0.0% YoY), and the annual figure for FY2023 was $445.0 million, changed.
Asset Writedowns and Impairment for Q1 2023 was $445.0 million at Clorox, up from $329.0 million in the prior quarter.
Over the last five years, Asset Writedowns and Impairment for CLX hit a ceiling of $445.0 million in Q1 2023 and a floor of $329.0 million in Q1 2021.